Carcinoma of unknown primary (CUP)
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Fizazi, K. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Fizazi, K. | en |
dc.date.accessioned | 2018-06-22T09:54:14Z | |
dc.date.available | 2018-06-22T09:54:14Z | |
dc.date.issued | 2009 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42258 | |
dc.description.abstract | Carcinoma of unknown primary (CUP) is one of the 10 most frequent cancers worldwide. It constitutes 3-5% of all human malignancies. Patients with CUP present with metastases without an established primary site. CUP manifests as an heterogenous group of mainly epithelial cancers recognised by distinct clinicopathological entities. The diagnostic work-up includes extensive histopathology investigations and modern imaging technology. Nevertheless, the primary tumour remains undetected most of the time. Molecular diagnosis with DNA microarrays demonstrates high sensitivity, but its prognostic contribution is still uncertain. Certain clinicopathological CUP entities are considered as favourable sub-sets responding to systemic platinum-based chemotherapy or managed by locoregional treatment. These sub-sets are: the poorly differentiated carcinomas involving the mediastinal-retroperitoneal nodes, peritoneal papillary serous adenocarcinomatosis in females, poorly differentiated neuroendocrine carcinomas, isolated axillary node adenocarcinomas in females or cervical nodal involvement by a squamous cell carcinoma. Patients who belong to the non-favourable sub-sets have a worse prognosis. © 2008 Elsevier Ireland Ltd. All rights reserved. | en |
dc.language.iso | eng | en |
dc.source | Critical reviews in oncology/hematology | en |
dc.subject | Antineoplastic agent | en |
dc.subject | Human | en |
dc.subject | Neoplasms | en |
dc.subject | Tamoxifen | en |
dc.subject | Humans | en |
dc.subject | Cancer patient | en |
dc.subject | Cancer combination chemotherapy | en |
dc.subject | Carboplatin | en |
dc.subject | Neoplasm staging | en |
dc.subject | Paclitaxel | en |
dc.subject | Prognosis | en |
dc.subject | Clinical trial | en |
dc.subject | Gemcitabine | en |
dc.subject | Taxane derivative | en |
dc.subject | Platinum | en |
dc.subject | Cancer staging | en |
dc.subject | Review | en |
dc.subject | Cancer surgery | en |
dc.subject | Erlotinib | en |
dc.subject | Metastasis | en |
dc.subject | Cancer diagnosis | en |
dc.subject | Cancer mortality | en |
dc.subject | Cancer radiotherapy | en |
dc.subject | Bone metastasis | en |
dc.subject | Irinotecan | en |
dc.subject | Risk factors | en |
dc.subject | Clinical feature | en |
dc.subject | Lymphatic metastasis | en |
dc.subject | Histopathology | en |
dc.subject | Cancer incidence | en |
dc.subject | Mediastinum lymph node | en |
dc.subject | Diagnosis | en |
dc.subject | Treatment | en |
dc.subject | Bevacizumab | en |
dc.subject | Adenocarcinoma | en |
dc.subject | Paraaortic lymph node | en |
dc.subject | Squamous cell carcinoma | en |
dc.subject | Diagnostic value | en |
dc.subject | Unknown primary | en |
dc.subject | Cancer localization | en |
dc.subject | Carcinoma | en |
dc.subject | Tumor marker | en |
dc.subject | Endoscopy | en |
dc.subject | Prostate specific antigen | en |
dc.subject | Protein blood level | en |
dc.subject | Differential | en |
dc.subject | Early diagnosis | en |
dc.subject | Patient referral | en |
dc.subject | Cancer of unknown primary | en |
dc.subject | Dna microarray | en |
dc.subject | Adjuvant therapy | en |
dc.subject | Diagnostic imaging | en |
dc.subject | Cancer tissue | en |
dc.subject | Chromosome aberration | en |
dc.subject | Primary tumor | en |
dc.subject | Brain cancer | en |
dc.subject | Endocrine tumor | en |
dc.subject | Tissue differentiation | en |
dc.subject | Uterine cervix | en |
dc.title | Carcinoma of unknown primary (CUP) | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1016/j.critrevonc.2008.09.005 | |
dc.description.volume | 69 | |
dc.description.issue | 3 | |
dc.description.startingpage | 271 | |
dc.description.endingpage | 278 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |